论文部分内容阅读
目的:观察孟鲁司特联合桂龙咳喘宁治疗轻度支气管哮喘的临床疗效。方法:89例非急性发作期轻度哮喘患者随机分为两组,联用组予孟鲁司特10mg,qd,桂龙咳喘宁1.5g,tid。对照组予布地奈德200μg,bid。疗程均为6周。结果:与治疗前相比,两组平均日间哮喘症状评分、血清IL-5水平均有明显降低,肺功能指标FEV1和PEF占预计值的百分比则明显增加,两组间相比差异无统计学意义。两组均未出现严重不良反应。结论:孟鲁司特联合桂龙咳喘宁治疗轻度哮喘具有可靠疗效,无明显不良反应。
Objective: To observe the clinical efficacy of montelukast combined with Guilong Kechuanning in the treatment of mild bronchial asthma. Methods: A total of 89 mild asthma patients without acute exacerbation were randomly divided into two groups. The combination group was given montelukast 10 mg, qd, Guilong Kechuanning 1.5 g, tid. The control group was given budesonide 200μg, bid. The course of treatment is 6 weeks. Results: Compared with those before treatment, the mean daytime asthma symptom scores and serum IL-5 levels were significantly decreased in both groups, and the percentage of predicted FEV1 and PEF was significantly increased in both groups, with no significant difference between the two groups Significance of learning. No serious adverse reactions occurred in either group. Conclusion: Montelukast combined with Guilong Kechuanning treatment of mild asthma has a reliable effect, no significant adverse reactions.